Back to Journals » Journal of Hepatocellular Carcinoma » Volume 5

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

Authors Gilabert M, Raoul JL

Received 9 July 2018

Accepted for publication 10 September 2018

Published 2 November 2018 Volume 2018:5 Pages 91—98


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Ahmed Kaseb

Marine Gilabert,1,2 Jean-Luc Raoul3

1Department of Medical Oncology, Paoli-Calmettes Institute, 13232 Marseille Cedex 9, France; 2Centre de Recherche en Cancérologie de Marseille, Stress Cell Unit, Institut National de la Sante et de la Recherche Medicale 1068, Aix-Marseille University, Cedex 8, Marseille, France; 3Department of Medical Oncology, Institut de Cancérologie de l’Ouest René Gauducheau, 44805 Nantes, France

Abstract: Hepatocellular carcinoma (HCC) represents ~90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first- and second-line treatment. This study focused on the efficacy of antiangiogenics in patients with advanced HCC and particularly the rising role of ramucirumab in patients with elevated alpha-fetoprotein at diagnosis.

Keywords: hepatocellular carcinoma, antiangiogenic drugs, ramucirumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]